AstraZeneca and Merck & Co. Inc. announced Lynparza (olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.
AstraZeneca said the company’s Enhertu cancer drug has been shown to significantly help women suffering from a type of breast cancer that leaves them with poor treatment options, opening the door to a much larger potential patient group.
Daiichi Sankyo and AstraZeneca reported positive topline data from their head-to-head DESTINY-Breast-03 Phase III trial for Enhertu versus trastuzumab emtansine (T-DM1) in patients with HER2 positive metastatic breast cancer.
In the RELATIVITY-047 Phase II/III trial combining Bristol Myers Squibb’s Opdivo with the anti-LAG-3 antibody relatlimab, the drug mashup met the study’s primary goal for progression-free survival compared to use of the blockbuster brand alone in metastatic melanoma patients.
After touting positive results in December and August 2020 for the company’s Phase III cancer medicine for metastatic breast cancer, Odonate Therapeutics is discontinuing drug development and closing up shop.
Gilead Sciences Inc. and Immunomedics announced that the companies entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash.
An experimental drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, in the first clinical study for trastuzumab deruxtecan.
Novartis said Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose the drug over Pfizer’s blockbuster Ibrance.
Novartis’ Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit the key secondary endpoint, overall survival.
The European Commission approved Pfizer Inc.’s Talzenna (talazoparib), an oral polypolymerase inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene 1/2-mutations who have human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer.